Provided by Tiger Fintech (Singapore) Pte. Ltd.

Aerovate Therapeutics, Inc.

9.80
+0.0000
Volume:- -
Turnover:- -
Market Cap:284.05M
PE:-5.76
High:9.80
Open:9.80
Low:9.80
Close:9.80
Loading ...

Company Profile

Company Name:
Aerovate Therapeutics, Inc.
Exchange:
NASDAQ
Establishment Date:
- -
Employees:
- -
Office Location:
- -
Zip Code:
- -
Phone:
- -
Fax:
- -
Introduction:
Aerovate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops drugs that enhance the lives of patients with rare cardiopulmonary diseases in the United States. It focuses on advancing AV-101, a dry powder inhaled formulation of imatinib for the treatment of pulmonary arterial hypertension, which is in Phase 2b/Phase 3 trial. The company was incorporated in 2018 and is headquartered in Waltham, Massachusetts.